OncoSil Lands Rapid Oral Slot at ESMO GI 2026 After Hitting Study Endpoints
OncoSil secures rapid oral presentation slot at ESMO GI 2026 for TRIPP-FFX study
OncoSil Medical (ASX: OSL) has received notification that its TRIPP-FFX study abstract has been selected for a Rapid Oral Presentation at the European Society for Medical Oncology Gastrointestinal Cancers Congress 2026 (ESMO GI 2026) in Munich, Germany. The presentation is scheduled for 4 July 2026 at 08:30 CEST (4:30pm AEST), positioning the company’s clinical data before one of the world’s leading scientific audiences focused on gastrointestinal cancers.
The selection follows the company’s recent announcement on 9 June 2026 that the TRIPP-FFX study achieved its co-primary endpoints. ESMO GI, which runs from 1-4 July 2026, is recognised as one of the most influential international scientific congresses dedicated to gastrointestinal cancers, providing a high-profile platform for OncoSil to present its findings to leading specialists and key opinion leaders globally.
When big ASX news breaks, our subscribers know first
What is a rapid oral presentation and why does it matter?
A Rapid Oral Presentation represents a competitively selected speaking slot where researchers present findings directly to congress attendees, distinct from poster presentations that receive less visibility and engagement. The selection process is highly competitive, reflecting peer recognition of the clinical significance and scientific merit of the presented research.
At ESMO GI 2025, 3,792 participants from 103 countries attended the congress, with 453 abstracts presented. Of these, only 4 were selected as late-breaking abstracts, underscoring the selectivity of the programme. The inclusion of the TRIPP-FFX study as a Rapid Oral Presentation places OncoSil’s clinical data among a highly selective group chosen for presentation to one of the largest audiences in gastrointestinal oncology.
For investors, oral presentations at major oncology congresses serve as validation of scientific merit and attract attention from potential strategic partners, clinicians, and researchers. Selection among such a competitive field signals international interest in the clinical potential of the OncoSil device and positions the company to elevate awareness among decision-makers who influence adoption and partnership discussions.
TRIPP-FFX study achieves co-primary endpoints
The accepted abstract is titled: “TRIPP-FFX: An open-label, multi-centre, randomised study of TaRgeted Intratumoural Placement of Phosphorous-32 microparticles added to FOLFIRINOX (FFX) versus FFX alone in patients with unresectable locally advanced pancreatic cancer (LAPC).”
The study evaluated the safety and efficacy of the OncoSil device when added to FOLFIRINOX chemotherapy in patients with unresectable locally advanced pancreatic cancer. The company announced on 9 June 2026 that the study achieved its co-primary endpoints, with the ESMO GI presentation scheduled to include findings from this evaluation.
The TRIPP-FFX trial results published on 9 June 2026 confirmed an 82.2% local disease control rate at 16 weeks, comfortably exceeding the pre-specified 75% target threshold, alongside median overall survival of 18.3 months in the OncoSil plus FOLFIRINOX arm.
Key study characteristics include:
- Study type: Open-label, multi-centre, randomised
- Treatment arm: OncoSil + FOLFIRINOX
- Control arm: FOLFIRINOX alone
- Patient population: Unresectable locally advanced pancreatic cancer
The combination of positive endpoint data with a major congress presentation strengthens the clinical evidence base supporting regulatory and commercial discussions. The presentation will provide detailed findings from the trial to an international audience of gastrointestinal cancer specialists.
Understanding locally advanced pancreatic cancer and the OncoSil device
Unresectable locally advanced pancreatic cancer (LAPC) refers to cancer that cannot be surgically removed but has not spread to distant organs. This patient population faces limited treatment options and poor prognosis, representing a significant unmet medical need in oncology.
The OncoSil device utilises targeted intratumoural placement of Phosphorous-32 microparticles to deliver radiation directly into the tumour. This approach enables healthcare professionals to deliver a greater radiation dose directly to the cancerous tissue compared to external beam radiotherapy, while sparing surrounding critical organs from radiation exposure.
Nigel Lange, CEO & Managing Director
“The selection of TRIPP-FFX as a Rapid Oral Presentation at ESMO GI 2026 is an important milestone for OncoSil Medical and a strong endorsement of the scientific significance of our study. …”
Pancreatic cancer is the 12th most common cancer in men and the 11th most common cancer in women globally, with 500,000 new cases detected annually. The disease is generally diagnosed at a later stage, contributing to poor prognosis for long-term survival. This large addressable patient population with significant unmet medical need underpins the commercial opportunity for interventional oncology devices like OncoSil.
Regulatory footprint and commercial progress
OncoSil has received CE Marking approval, providing marketing authorisation in both the European Union and the United Kingdom. The device is designated as a breakthrough device in both Europe and the United States, and is currently approved for sale in 30+ countries including the European Union, United Kingdom, Australia, Türkiye, and Israel.
Commercial treatments using the OncoSil device have already been undertaken in Spain, Italy, Austria, Germany, Greece, Türkiye, Portugal, Israel, and the UK, demonstrating established commercial activity across multiple geographies.
| Region | Regulatory Status | Commercial Status |
|---|---|---|
| European Union | CE Marking approved | Treatments in Spain, Italy, Austria, Germany, Greece, Portugal |
| United Kingdom | CE Marking approved | Commercial treatments undertaken |
| United States | Breakthrough Device designation | Not disclosed |
| Australia | Approved for sale | Approved |
| Türkiye | Approved for sale | Commercial treatments undertaken |
| Israel | Approved for sale | Commercial treatments undertaken |
This existing commercial footprint across multiple geographies provides a revenue pathway as the clinical evidence base expands through studies like TRIPP-FFX. The breakthrough device designation in the United States suggests an advancing regulatory pathway in a key market, while established commercial activity in Europe and other approved markets demonstrates active adoption by healthcare providers.
Alongside the European clinical momentum, OncoSil’s FDA Humanitarian Device Exemption application reached its final administrative stage in June 2026, with the FDA having resolved all substantive review questions and a decision targeted within 75 days, pointing to a potential US market entry in 2H CY2027.
Strategic implications of the ESMO GI presentation
The ESMO GI presentation represents an opportunity to elevate OncoSil awareness among leading clinicians, researchers, and potential strategic stakeholders globally. Following the achievement of co-primary endpoints announced in June 2026, the timing of the presentation amplifies the strategic value of the clinical data by placing it before one of the most influential audiences in gastrointestinal oncology.
Nigel Lange, CEO & Managing Director
“Following the achievement of the study’s co-primary endpoints, we are excited to present the TRIPP-FFX findings to one of the most influential audiences in gastrointestinal oncology. The opportunity to showcase our data at ESMO GI further elevates awareness of OncoSil among leading clinicians, researchers and potential strategic stakeholders globally. We believe this presentation represents another important step in building the clinical evidence base supporting OncoSil™ and advancing our regulatory and commercial objectives in key markets.”
Congress presentations often serve as catalysts for partnership discussions and clinician adoption, particularly when accompanied by positive clinical data. The combination of endpoint achievement and a high-profile speaking slot at ESMO GI 2026 positions OncoSil to engage with key opinion leaders and decision-makers who influence treatment protocols and device adoption across international markets.
The next major ASX story will hit our subscribers first
What’s next for OncoSil Medical
The immediate focus for OncoSil Medical centres on the ESMO GI 2026 presentation scheduled for 4 July 2026. This near-term catalyst provides a defined timeline for additional market visibility and an opportunity to present detailed TRIPP-FFX findings to the international gastrointestinal oncology community.
Beyond the July presentation, the company continues advancing regulatory and commercial objectives across its approved markets. The breakthrough device designation in the United States suggests ongoing regulatory pathway progression in a key market, whilst established commercial activity in Europe, Australia, Türkiye, and Israel provides a foundation for expanded adoption as the clinical evidence base strengthens.
The presentation at one of the world’s leading gastrointestinal cancer congresses, combined with the competitive selection process and timing alongside positive endpoint data, positions OncoSil to build momentum in both clinical awareness and commercial traction during the second half of 2026.
Want the Next Biotech Breakthrough in Your Inbox?
Join 20,000+ investors receiving FREE breaking ASX healthcare news within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to get real-time alerts on market-moving biotech announcements before the market reacts.